SpyGlass Pharma (SGP) Registration Filing summary

Company overview and business model

• Late-stage biopharmaceutical company focused on long-acting, sustained drug delivery for chronic eye conditions, primarily glaucoma and ocular hypertension.

• Lead product is the BIM-IOL System, an intraocular lens with drug pads delivering bimatoprost over three years, implanted during cataract surgery.

• Pipeline includes a non-IOL-based, ring-shaped sustained-release implant (BIM-DRS) and early-stage programs for other eye diseases.

• Business model leverages known drugs, procedures, and devices to streamline regulatory approval and market adoption.

Financial performance and metrics

• No revenue to date; net losses of $29.2M (2024), $13.3M (2023), and $27.3M for the nine months ended September 30, 2025.

• Accumulated deficit of $92.2M as of September 30, 2025.

• Cash, cash equivalents, and short-term investments of $118.0M as of September 30, 2025.

• Research and development expenses increased 51% year-over-year for the nine months ended September 30, 2025.

Use of proceeds and capital allocation

• Estimated net proceeds of $135.2M (or $156.1M if underwriters' option exercised) based on a $16.00/share IPO price.

• Proceeds to fund completion of two Phase 3 trials, potential commercial launch of the BIM-IOL System, further R&D (including BIM-DRS), and general corporate purposes.

• Management has broad discretion over use of proceeds.